Get the Stockscreener App
3.20
0.63%
0.02
After Hours:
3.14
-0.06
-1.88%
Cyclerion Therapeutics Inc stock is traded at $3.20, with a volume of 29,228.
It is up +0.63% in the last 24 hours and up +8.84% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$3.18
Open:
$3.08
24h Volume:
29,228
Relative Volume:
0.01
Market Cap:
$13.86M
Revenue:
$2.07M
Net Income/Loss:
$-3.53M
P/E Ratio:
-2.7204
EPS:
-1.1763
Net Cash Flow:
$-3.31M
1W Performance:
+6.67%
1M Performance:
+8.84%
6M Performance:
+110.53%
1Y Performance:
-2.14%
1-Day Range:
$3.01
$3.20
1-Week Range:
$2.98
$3.35
52-Week Range:
$1.0266
$8.48
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.20 | 13.77M | 2.07M | -3.53M | -3.31M | -1.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Cyclerion Shares to Watch With Deal in Focus as Markets Reopen - Bez Kabli
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
TradingKey - TradingKey
CYCN News | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
Why Cyclerion (CYCN) deserves a deeper look right now (-2.78%) 2026-05-07Insider Info - newser.com
FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G - Stock Titan
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - Sahm
CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Cyclerion Therapeutics 2024 10-K/A Amendment: Executive Compensation, Governance, and Equity Awards Overview - Minichart
Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details - Stock Titan
CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN
CYCN SEC FilingsCyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy - HarianBasis.co
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline - Insider Monkey
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is Cyclerion (CYCN) stock outperforming similar companies (Drifts Higher) 2026-04-18Open Stock Signal Network - Xã Thanh Hà
EDGAR Filing Documents for 0001193125-26-162177 - SEC.gov
Published on: 2026-04-13 23:21:17 - baoquankhu1.vn
Guidance Update: Is Cyclerion Therapeutics Incs growth already priced inEarnings Recap Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - Citeline News & Insights
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? - Finviz
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Sharehol - GuruFocus
Fed Watch: Is Cyclerion Therapeutics Incs growth already priced inQuarterly Earnings Summary & AI Optimized Trade Strategies - baoquankhu1.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSENSA), Urgent.ly, Inc. (OTC MarketsULYX), UniFirst Corporation (NYSEU - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rate Hike: Is Cyclerion Therapeutics Incs growth already priced in2026 Historical Comparison & Expert Approved Momentum Ideas - baoquankhu1.vn
Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Alzheimer’s company Korsana heads to NASDAQ via merger: Deals Report - BioCentury
Monday's session: gap up and gap down stocks - ChartMill
Penny stock CYCN surged more than 300% yesterday. Why, and should you chase the rally here? - MSN
CYCN PE Ratio & Valuation, Is CYCN Overvalued - Intellectia AI
CYCN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
If You Invested $1,000 in Cyclerion Therapeutics Inc (CYCN) - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) - Sahm
Korsana Biosciences and Cyclerion Therapeutics Announce All-Stock Merger and $380 Million Financing - Global Legal Chronicle
Monteverde & Associates Investigates Cyclerion Therapeutics Merger - National Today
CYCN Plunges 17% After Merger Announcement: What’s Next for Cyclerion and Korsana? - Bitget
Cyclerion and Korsana Tie the Knot with a New Merger Strategy - StocksToTrade
Cyclerion Therapeutics Merger Sparks Investor Uncertainty - timothysykes.com
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? - Barchart.com
Korsana boosts Alzheimer’s work with reverse merger, $380M financing - BioWorld News
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cycle - The National Law Review
Cyclerion Therapeutics and Korsana Biosciences Announce $380M Merger to Advance Alzheimer’s Treatment KRSA-028 - Minichart
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):